• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Cuba grants emergency approval to second homegrown vaccine

firstwordpharmaAugust 23, 2021

Tag: Cuba , COVID-19 , Vaccine

Cuba's Center for State Control of Medicines, Equipment and Medical Devices granted emergency approval to the Soberana 2 vaccine for the prevention of COVID-19, as reported in National Post.

Cuba grants emergency approval to second homegrown vaccine

Approval means the vaccine, which is comprised of two initial shots and a booster, can be included in the national immunisation programme.

The Soberana 2 vaccine is said to have an efficacy rate of 91.2% and has already been used in Cuba to vaccinate some health workers and ordinary citizens in areas with high rates of transmission.


Previous:Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer

Next:Spotting the Signs of Deadly Melanoma Skin Cancers

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Cuba grants emergency approval to second homegrown vaccine | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Thermostatic Horizontal Shaking Incubator SSRT30

Thermostatic Horizontal Shaking Incubator SSRT30
Varicella Vaccine, Live

Varicella Vaccine, Live
Microplate incubator SMI400

Microplate incubator SMI400
Biochemistry Incubator

Biochemistry Incubator
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Poultry Vaccine Series 2

Poultry Vaccine Series 2
Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)
Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production

Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production
Sacubatril/Valsartan

Sacubatril/Valsartan
IPV(Inactivated Poliovirus Vaccine)

IPV(Inactivated Poliovirus Vaccine)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service